Femtobiomed Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 12

Employees

  • Stock Symbol
  • 327610

Stock Symbol

  • Share Price
  • $6.29
  • (As of Friday Closing)

Femtobiomed General Information

Description

Femtobiomed Inc is a South Korea based company engaged in developing a cargo-free intracellular delivery platform called Cell Shot Platform. It is focused on using this technology to work on cell-based therapeutic pipelines.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
KRX
Corporate Office
  • 17 Pangyoro-228-beon-gil
  • Bundang-gu
  • Seongnam-si, Gyeonggi-do
  • South Korea
+82 000-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Femtobiomed Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.29 $6.34 $3.50 - $8.11 $52.9M 8.4M 3.08K -$0.20

Femtobiomed Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 34,850 34,850 76,358 124,939
Revenue 255 255 142 201
EBITDA (1,239) (1,239) (459) (7,590)
Net Income (1,720) (1,720) (948) (8,151)
Total Assets 2,551 2,551 3,224 3,851
Total Debt 233 233 224 301
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Femtobiomed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Femtobiomed‘s full profile, request access.

Request a free trial

Femtobiomed Patents

Femtobiomed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240117291-A1 Cell transformation cartridge, cell transformation device, cell transformation system including same and cell transformation method using same Pending 07-Oct-2022 000000000
EP-3882332-A1 Method and apparatus for controlling intracellular delivery of materials Inactive 12-Nov-2018 000000000
EP-3882332-A4 Method and apparatus for controlling intracellular delivery of materials Inactive 12-Nov-2018 000000000 0
JP-6799086-B2 Method for quantifying hydrophobic components in liquid using contact surface diffusion coefficient and method for providing information for diagnosis of diseases using this method Active 26-Apr-2017 000000000
JP-2019521338-A Method of quantifying hydrophobic component in liquid using contact surface diffusion coefficient and method of providing information for diagnosis of disease using the same Active 26-Apr-2017 G01N13/02
To view Femtobiomed’s complete patent history, request access »

Femtobiomed Executive Team (2)

Name Title Board Seat Contact Info
Sang-Hyun Lee Ph.D Founder & Chief Executive Officer
You’re viewing 1 of 2 executive team members. Get the full list »

Femtobiomed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Femtobiomed Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Femtobiomed‘s full profile, request access.

Request a free trial

Femtobiomed FAQs

  • When was Femtobiomed founded?

    Femtobiomed was founded in 2011.

  • Who is the founder of Femtobiomed?

    Sang-Hyun Lee Ph.D is the founder of Femtobiomed.

  • Who is the CEO of Femtobiomed?

    Sang-Hyun Lee Ph.D is the CEO of Femtobiomed.

  • Where is Femtobiomed headquartered?

    Femtobiomed is headquartered in Seongnam-si, South Korea.

  • What is the size of Femtobiomed?

    Femtobiomed has 12 total employees.

  • What industry is Femtobiomed in?

    Femtobiomed’s primary industry is Biotechnology.

  • Is Femtobiomed a private or public company?

    Femtobiomed is a Public company.

  • What is Femtobiomed’s stock symbol?

    The ticker symbol for Femtobiomed is 327610.

  • What is the current stock price of Femtobiomed?

    As of 14-Jun-2024 the stock price of Femtobiomed is $6.29.

  • What is the current market cap of Femtobiomed?

    The current market capitalization of Femtobiomed is $52.9M.

  • What is Femtobiomed’s current revenue?

    The trailing twelve month revenue for Femtobiomed is $255K.

  • What is Femtobiomed’s annual earnings per share (EPS)?

    Femtobiomed’s EPS for 12 months was -$0.20.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »